PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBotulinum toxin type a
Botulinum toxin type a
Nuceiva (botulinum toxin type a) is a protein pharmaceutical. Botulinum toxin type a was first approved as Nuceiva on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
digestive system diseasesD004066
nervous system diseasesD009422
eye diseasesD005128
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
integumentary system physiological phenomenaD055827
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
daxxifyBiologic Licensing Application2024-01-24
dysportBiologic Licensing Application2024-10-24
protoxinunapproved drug other2016-11-10
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1353 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Skin agingD015595EFO_0005422—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBotulinum toxin type a
INN—
Description
Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
Classification
Neurotoxin
Drug classfluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4297862
ChEBI ID—
PubChem CID—
DrugBankDB00083
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,950 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daxxify, Dysport
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,113 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use